This report discusses the trends, tracking expectations across capacity, processing, and other demands.
Facing internal pressures alongside external ones, organizations are rethinking how they bring their therapeutics to market—including their choice of outsourcing partnerships with contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs).
A recent survey from BioPharma Dive and Cytiva explored these trends, asking emerging biotechs about their current pipelines, intentions for the future, and expectations for selected partners. This survey report discusses those findings, tracking shifting sentiments and confidence in manufacturing capacity, processing, and other workflows. You’ll learn:
Offered Free by: BioPharma Dive's studioID and Cytiva
See All Resources from: BioPharma Dive's studioID and Cytiva